<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198078</url>
  </required_header>
  <id_info>
    <org_study_id>331-10-234</org_study_id>
    <nct_id>NCT03198078</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Safety &amp; Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety &amp; efficacy of brexpiprazole monotherapy in the treatment of
      adolescents with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo- and active-controlled trial to
      evaluate the safety and efficacy of brexpiprazole monotherapy compared to placebo in
      adolescent subjects (ages 13-17) with a DSM-5 diagnosis of schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects randomized 1:1:1 to 1 of 3 double-blind treatment arms to evaluate safety &amp; efficacy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) Score</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall change in Positive and Negative Subscale Scores</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS Response Percentage</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Response defined as at least 30% improvement from baseline in PANSS Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Children's Global Assessment Scale (CGAS) Score</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression Severity (CGI-S) Score</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression Improvement (CGI-I) Score</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events (AEs), Serious AEs (clinical &amp; laboratory) [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination with a 21 day follow-up period</time_frame>
    <description>Frequency and severity will be monitored; along with serious AEs &amp; discontinuation from trial due to AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Exam [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Physical exams will be performed to assess any changes in subject over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Change in vital signs will be assessed for any notable differences from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Change in weight, in kilograms, will be assessed for any notable differences from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Change in height, in centimeters, will be assessed for any notable differences from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI) [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Measured in kg/m^2 and assessed to determine any notable differences from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
    <description>Change in waist circumference, in centimeters will be assessed for any notable differences from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential suicide events recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS) [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Laboratory tests (hematology, serum chemistry [including blinded prolactin] and urinalysis) Results [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Simpson Angus Scale (SAS) Scores [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Abnormal Involuntary Movement Scale (AIMS) Score [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Barnes Akathisia Rating Scale (BARS) Scores [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive psychotropic side effects as assessed by Udvalg for Kliniske Undersogelser (UKU) [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Adverse effects assessed by New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT) [Safety]</measure>
    <time_frame>Up to 6 weeks or early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">387</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole (OPC-34712)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-4 mg/day; Start at 0.5 mg/day, titrate to max of 4 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10-20 mg/day; Start at 2 mg per day, titrate up to max of 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole (OPC-34712)</intervention_name>
    <description>Once-daily, tablets</description>
    <arm_group_label>Brexpiprazole (OPC-34712)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Once-daily, tablets</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once-daily, tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male &amp; female subjects aged 13-17 years, inclusive at time of consent with a primary
             diagnosis of schizophrenia as defined by DSM-5 criteria and confirmed by K-SADS-PL and
             a history of the illness for at least 6 months prior to screening.

          -  Subjects have shown previous response to antipsychotic treatment other than clozapine.

          -  Subjects with a history of relapse or exacerbation of symptoms when not receiving
             antipsychotic treatment

          -  Outpatient status at screening and within 21 days of baseline visit.

          -  PANSS score &gt;= 80, inclusive, at screening and baseline

        Exclusion Criteria:

          -  Subjects with a current primary DSM-5 diagnosis other than schizophrenia, including
             any DSM-5 current diagnosis of schizoaffective disorder or current diagnosis of major
             depressive disorder, PTSD, or bipolar disorder with or without psychotic features

          -  Subjects with any of the following DSM-5 diagnoses: borderline, paranoid, histrionic,
             schizotypal, schizoid, or antisocial personality disorder.

          -  Subjects with a clinical presentation or history that is consistent with delirium,
             dementia, amnesia or other cognitive disorders

          -  Subjects who have been hospitalized &gt; 21 days for acute exacerbation of schizophrenia
             at the time of the baseline visit

          -  Any neurological disorder other than Tourette's Syndrome

          -  Subjects at significant risk of committing violent acts, serious self-harm or suicide
             based on history

          -  Subjects with epilepsy, a history of seizures, severe head trauma or stroke

          -  Subjects who test positive for drugs of abuse at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Kohegyi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharamceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Pokorny</last_name>
    <phone>+1-919-745-2685</phone>
    <email>Jennifer.Pokorny@INCResearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CMB Clinical Trials LLC</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Wellness dba Alliance for Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Behavioral Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30388</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Hope Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charak Clinical Research Center</name>
      <address>
        <city>Garfield Heights</city>
        <state>Ohio</state>
        <zip>44125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Red River Medical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin P.C.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastside Therapeutic Resource dba Core Clinical Research</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brexpiprazole</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

